Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of BNT162b2 in Healthy Japanese Adults
NCT04588480Phase 4Completed
- Sponsor
- BioNTech SE
- Start
- Oct 2020
- Primary completion
- Nov 2021
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by BioNTech SE. Started Oct 2020; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04588480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04588480.